Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. Our first commercial product, Jakafi® (ruxolitinib), is approved in the United States for patients with intermediate or high-risk myelofibrosis and for patients with polycythemia vera who have had an inadequate response to or are intolerant to hydroxyurea. We have a diverse and growing portfolio of product candidates, including both small and large molecules.
Events & Presentations
8:00 AM EST
Q4 2018 Incyte Corporation Earnings Conference Call
2:00 PM PST
J. P. Morgan 37th Annual Healthcare Conference Q/A Session
1:30 PM PST
J. P. Morgan 37th Annual Healthcare Conference Presentation